Understanding Clinical Innovation

Here’s how clinical innovation translates to a new drug’s success:

Oncology Insights

Featured
How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC
Alecensa, Genentech, NSCLC, Xalkori
How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC
Alecensa, Genentech, NSCLC, Xalkori
Read More →
Alecensa, Genentech, NSCLC, Xalkori
Screenshot 2025-10-30 154345.png
Indication Prioritization, Oncology, Disease Area Strategy
What indications should we focus on?
Indication Prioritization, Oncology, Disease Area Strategy
Read More →
Indication Prioritization, Oncology, Disease Area Strategy
Enhertu regimen Figure (1).jpg
Enhertu, breast cancer, AstraZeneca, Daiichi-Sankyo
Enhertu is poised to dominate first-line HER2+ breast cancer
Enhertu, breast cancer, AstraZeneca, Daiichi-Sankyo
Read More →
Enhertu, breast cancer, AstraZeneca, Daiichi-Sankyo
Cost Benefit Yescarta CAR T post.png
Yescarta, Breyanzi, Carvykti, DLBCL, Multiple Myeloma, Kite, Bristol Myers Squibb, Janssen
CAR-T Outlook
Yescarta, Breyanzi, Carvykti, DLBCL, Multiple Myeloma, Kite, Bristol Myers Squibb, Janssen
Read More →
Yescarta, Breyanzi, Carvykti, DLBCL, Multiple Myeloma, Kite, Bristol Myers Squibb, Janssen
Enhertu-vs.-Kadcyla.jpg
Enhertu, Daiichi-Sankyo, AstraZeneca, Breast Cancer
Enhertu shows high clinical innovation in second-line metastatic breast cancer
Enhertu, Daiichi-Sankyo, AstraZeneca, Breast Cancer
Read More →
Enhertu, Daiichi-Sankyo, AstraZeneca, Breast Cancer
Keytruda-and-Lenvima-Figure.jpg
Keytruda, Merck, Eisai, Lenvima, RCC
Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC
Keytruda, Merck, Eisai, Lenvima, RCC
Read More →
Keytruda, Merck, Eisai, Lenvima, RCC
amivantamab figure jpeg.jpg
Rybrevant, Exkivity, Janssen, Takeda, NSCLC
Rybrevant and Exkivity: two highly innovative new therapies to treat EGFR Exon 20 Insertion positive mNSCLC
Rybrevant, Exkivity, Janssen, Takeda, NSCLC
Read More →
Rybrevant, Exkivity, Janssen, Takeda, NSCLC
Capture3.JPG
Prioritizing Indications: An Analytical Framework
Read More →
drivers.png
Trodelvy, TNBC, Gilead
Trodelvy: A New Option for Later Lines TNBC
Trodelvy, TNBC, Gilead
Read More →
Trodelvy, TNBC, Gilead
Onco Drivers.PNG
Monjuvi, lenalidomide, DLBCL, Incyte
Monjuvi: Newest Blockbuster in Relapsed/Refractory DLBCL
Monjuvi, lenalidomide, DLBCL, Incyte
Read More →
Monjuvi, lenalidomide, DLBCL, Incyte
Two indications.PNG
Rozlytrek, Brain Mets, Xalkori, ROS1
Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study
Rozlytrek, Brain Mets, Xalkori, ROS1
Read More →
Rozlytrek, Brain Mets, Xalkori, ROS1
Drivers.JPG
Melanoma, Pfizer, Braftovi, Mektovi
Pfizer Combo Gains an Edge in BRAF+ Melanoma
Melanoma, Pfizer, Braftovi, Mektovi
Read More →
Melanoma, Pfizer, Braftovi, Mektovi
A Reliable Predictor of NICE Recommendation
NICE
A Reliable Predictor of NICE Recommendation
NICE
Read More →
NICE
Table.JPG
Brukinsa, MCL, Mantle Cell Lymphoma
Brukinsa: Shooting behind the duck in R/R mantle cell lymphoma
Brukinsa, MCL, Mantle Cell Lymphoma
Read More →
Brukinsa, MCL, Mantle Cell Lymphoma
Drivers website.JPG
Xtandi, Zytiga, HRRm, Lynparza, prostate cancer
Lynparza: Expanding into Prostate Cancer
Xtandi, Zytiga, HRRm, Lynparza, prostate cancer
Read More →
Xtandi, Zytiga, HRRm, Lynparza, prostate cancer
Screenshot 2025-09-19 094758.png
Keytruda, drug pricing, NSCLC
Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda
Keytruda, drug pricing, NSCLC
Read More →
Keytruda, drug pricing, NSCLC
drivers correct.JPG
Enhertu, breast cancer, AstraZeneca, HER2+
Enhertu: A New Leader in Later-Line Breast Cancer
Enhertu, breast cancer, AstraZeneca, HER2+
Read More →
Enhertu, breast cancer, AstraZeneca, HER2+
Zejula Updated.JPG
Zejula, Lynparza, BRCA-mutated, maintenance therapy, ovarian, pancreatic
PARP Inhibitors: Promise in New Maintenance Indications
Zejula, Lynparza, BRCA-mutated, maintenance therapy, ovarian, pancreatic
Read More →
Zejula, Lynparza, BRCA-mutated, maintenance therapy, ovarian, pancreatic
now onco.png
Candidate Observations to Be Added to Equinox’s Oncology Normative Pricing Model
Read More →
Capture.JPG
Tecentriq and Imfinzi Both Offer Modest Improvements in SCLC
Read More →
Capture.JPG
drug pricing
Pricing a new oncology agent across multiple indications
drug pricing
Read More →
drug pricing
Drivers for Calquence.PNG
Calquence: The price is right
Read More →
dfsdf.png
How to Price an Oncology Drug
Read More →
imbruvica 1.JPG
Imbruvica: Closing the window of opportunity in CLL
Read More →
Keytruda: Exceptional early results in a small colorectal cancer population
Read More →
Blincyto: High price for an undifferentiated drug
Read More →
opdivo 1.png
PD-1 Inhibitors: Strong starts in three indications
Read More →
avastin.png
Avastin: One molecule in multiple cancers
Read More →
Kyprolis: A rapid rise in a crowded market
Read More →